Apellis Pharmaceuticals

About Apellis Pharmaceuticals

At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8

Website	https://apellis.com/
Employees	501-1,000 employees View all Apellis Pharmaceuticals employees
Industry	Biotechnology
Location	100 Fifth Ave, 3rd Floor, Waltham, MA 02451, US
Founded	2008
Keywords	Gene Therapy, Neurology, Ophthalmology, Hematology, Nephrology, Nephrology, Neurology, Amyotrophic Lateral Sclerosis (Als), C3 Glomerulopathy (C3G), Cold Agglutinin Disease (Cad), Complement System, Geographic Atrophy (Ga), Paroxysmal Nocturnal Hemoglobinuria (Pnh), Targeted C3 Therapies, Ophthalmology, Hematology, Gene Therapy